PHARMASSET - Another Step Towards Success!
Pharmasset (VRUS) announced top line data of PSI-7977 PhIIb, PROTON study (PSI-7977 400mg, QD + Peg-IFN/RBV) in HCV genotype-1 treatment naïve pts and Initiation of IFN-free PhIIb trial of PSI-7977 and PSI-938. Result promises of many advantage over launched PI’s (Incivek/vertex/JNJ and Victrelis/Merck) and others in the pipeline. For more details, please read our report released on 13th September, 2011 on VRUS titled “Another Step Towards Success”.
COMPANIES MENTIONED
PHARMASSET
PHARMASSET
